Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib
Constantine S. Tam, Ying Ou, Judith Trotman, Stephen Opat
Abstract
Among the approved BTK inhibitors, zanubrutinib is less prone to PK modulation by intrinsic and extrinsic factors, leading to more consistent, sustained therapeutic exposures and improved dosing convenience. Zanubrutinib PK/PD has translated into durable responses and improved safety, representing an important new treatment option for patients who benefit from BTK therapy.
Topics & Concepts
Bruton's tyrosine kinaseMedicineIbrutinibPharmacologyPharmacokineticsDosingPharmacodynamicsDrugAdverse effectTyrosine kinaseInternal medicineReceptorChronic lymphocytic leukemiaLeukemiaChronic Lymphocytic Leukemia ResearchChronic Myeloid Leukemia TreatmentsLymphoma Diagnosis and Treatment